Table 2.
HR of Death Associated With Clinical Features and Mutations in Univariable Analyses
| Variable | Univariable |
Adjusted* |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Blasts (≥ 5% v < 5%) | 1.84 | 1.05 to 3.21 | .032 | |||
| Conditioning regimen (nonmyeloablative v ablative) | 2.03 | 1.04 to 3.94 | .037 | |||
| Karyotype (complex v other) | 2.16 | 1.24 to 3.77 | .007 | |||
| Donor type (unrelated v related) | 2.05 | 1.07 to 3.90 | .029 | |||
| Genetic mutation (present v absent) | ||||||
| TP53 | 3.74 | 2.08 to 6.75 | < .001 | 2.30 | 1.10 to 4.81 | .027 |
| TET2 | 1.68 | 0.79 to 3.57 | .18 | 2.40 | 1.07 to 5.38 | .033 |
| DNMT3A | 1.44 | 0.77 to 2.69 | .26 | 2.08 | 1.00 to 3.26 | .049 |
| PRPF8 | 1.23 | 0.53 to 2.89 | .63 | 1.06 | 0.44 to 2.55 | .89 |
| SF3B1 | 1.08 | 0.43 to 2.71 | .87 | 2.33 | 0.85 to 6.42 | .1 |
| CBL | 1.07 | 0.39 to 2.98 | .89 | 0.99 | 0.35 to 2.87 | .99 |
| ZRSR2 | 0.92 | 0.29 to 2.95 | .89 | 1.01 | 0.31 to 3.66 | .98 |
| SRSF2 | 0.90 | 0.36 to 2.77 | .83 | 1.20 | 0.46 to 3.12 | .71 |
| KDM6B | 0.80 | 0.25 to 2.56 | .7 | 1.09 | 0.32 to 3.67 | .89 |
| AXSL1 | 0.74 | 0.40 to 1.37 | .34 | 0.75 | 0.38 to 1.47 | .4 |
| NRAS | 0.74 | 0.27 to 2.06 | .57 | 0.63 | 0.22 to 1.78 | .38 |
| RUNX1 | 0.70 | 0.32 to 1.55 | .38 | 0.70 | 0.30 to 1.64 | .41 |
| U2AF1 | 0.54 | 0.22 to 1.37 | .2 | 0.76 | 0.29 to 2.02 | .58 |
| SUZ12 | 0.50 | 0.12 to 2.05 | .33 | 0.68 | 0.15 to 3.11 | .62 |
| WT1 | 0.44 | 0.11 to 1.82 | .26 | 0.54 | 0.13 to 2.30 | .41 |
| JAK2 | 0.23 | 0.03 to 1.66 | .14 | 0.31 | 0.04 to 2.28 | .25 |
| PRPF40B | 0.22 | 0.03 to 1.56 | .13 | 0.19 | 0.03 to 1.43 | .11 |
Abbreviation: HR, hazard ratio.
*
Adjusted for blast percentage, conditioning regimen, complex karyotype, and donor type.